Back | Next |
home / stock / imtx / imtx message board
Subject | By | Source | When |
---|---|---|---|
TCR Bispecifics Programs | FACT-MASTER | investorshub | 11/19/2022 2:41:26 AM |
On October 24, 2022, $GSK provided Immatics with | FACT-MASTER | investorshub | 11/19/2022 2:31:34 AM |
Article is not a free article, link | FACT-MASTER | investorshub | 11/19/2022 2:11:01 AM |
From the 3rd quarter 10Q: | FACT-MASTER | investorshub | 11/19/2022 2:05:25 AM |
But it seems to be a strategic decision | Solarfuture | investorshub | 11/18/2022 9:01:20 AM |
It is Opdivo. From memory, the first patient | jondoeuk | investorshub | 11/17/2022 11:19:36 PM |
Thanks it's here in black and white: | FACT-MASTER | investorshub | 11/17/2022 7:04:30 PM |
That better explains the recent 100 million + | FACT-MASTER | investorshub | 11/17/2022 6:31:50 PM |
Confirmed here as well. | FACT-MASTER | investorshub | 11/17/2022 6:21:24 PM |
$GSK's cell therapy exodus continues https://endpts.com/gsks-cell-therapy-retrea | jondoeuk | investorshub | 11/17/2022 6:12:51 PM |
Oh, that could make sense. I think that's | Solarfuture | investorshub | 10/31/2022 8:04:09 AM |
I concur with that analysis. | FACT-MASTER | investorshub | 10/31/2022 2:02:57 AM |
Oh, thank you! | Solarfuture | investorshub | 10/26/2022 7:48:20 AM |
Interesting development here with $GSK | FACT-MASTER | investorshub | 10/25/2022 4:56:09 PM |
Looks very promising and professional! | Solarfuture | investorshub | 10/19/2022 2:47:36 PM |
New Corporate presentation October 18/22 | FACT-MASTER | investorshub | 10/18/2022 9:16:37 PM |
Both news are great in my eyes! I | Solarfuture | investorshub | 10/11/2022 3:44:21 AM |
$IMTX Capital Raise: | FACT-MASTER | investorshub | 10/10/2022 1:47:29 PM |
$IMTX news out: | FACT-MASTER | investorshub | 10/10/2022 1:46:00 PM |
I hope so,... and turning back to accumulation | FACT-MASTER | investorshub | 10/03/2022 1:14:21 AM |
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...